Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Foster

Showing results (1241-1250 of 1,472) with videos related to

Pageof 148
Sort By:
Gut|December 14, 2004
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis CA K P Lim, S D Taylor-Robinson, N Patel, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Hepatology|December 3, 2013
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trialD Shoeb, J Dearden, A Weatherall, et al.
Nature Communications|June 6, 2020
Human aminolevulinate synthase structure reveals a eukaryotic-specific autoinhibitory loop regulating substrate binding and product releaseHenry J Bailey, Gustavo A Bezerra, Jason R Marcero, et al.
Cell|November 18, 2008
FLO1 is a variable green beard gene that drives biofilm-like cooperation in budding yeastScott Smukalla, Marina Caldara, Nathalie Pochet, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patientsP Ramachandran, A Fraser, K Agarwal, et al.
Scientific Reports|November 15, 2017
Eph-B4 regulates adaptive venous remodeling to improve arteriovenous fistula patencyClinton D Protack, Trenton R Foster, Takuya Hashimoto, et al.
The International Journal on Drug Policy|May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UKZoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|June 29, 2020
A Multicenter Evaluation of Outcomes Following the Use of Nebulized Heparin for Inhalation Injury (HIHI2 Study)Courtney L Cox, Allyson M McIntire, Kimberly J Bolton, et al.
Pageof 148

Showing results (1241-1250 of 1,472) with videos related to

Sort By:
Pageof 148
Gut|December 14, 2004
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis CA K P Lim, S D Taylor-Robinson, N Patel, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Hepatology|December 3, 2013
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trialD Shoeb, J Dearden, A Weatherall, et al.
Nature Communications|June 6, 2020
Human aminolevulinate synthase structure reveals a eukaryotic-specific autoinhibitory loop regulating substrate binding and product releaseHenry J Bailey, Gustavo A Bezerra, Jason R Marcero, et al.
Cell|November 18, 2008
FLO1 is a variable green beard gene that drives biofilm-like cooperation in budding yeastScott Smukalla, Marina Caldara, Nathalie Pochet, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patientsP Ramachandran, A Fraser, K Agarwal, et al.
Scientific Reports|November 15, 2017
Eph-B4 regulates adaptive venous remodeling to improve arteriovenous fistula patencyClinton D Protack, Trenton R Foster, Takuya Hashimoto, et al.
The International Journal on Drug Policy|May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UKZoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar, Donald W Northfelt, Steven E Schild, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|June 29, 2020
A Multicenter Evaluation of Outcomes Following the Use of Nebulized Heparin for Inhalation Injury (HIHI2 Study)Courtney L Cox, Allyson M McIntire, Kimberly J Bolton, et al.
Pageof 148